Gastrointestinal: bowel irregularity, constipation aggravated, dyspepsia, dysphagia, dysplasia GI, epigastric pain, eructation, esophageal disorder, frequent stools, gastroenteritis, GI hemorrhage, GI symptoms not otherwise specified, hiccup, melena, mouth disorder, pharynx disorder, rectal disorder, serum gastrin increased, tongue disorder, tongue edema, ulcerative stomatitis, vomiting
For further information about unapproved drugs, click here
In an environment with elevated CD38 activity, such as seen in SSc lesional skin, administering NAD + precursors or enhancing NAD + synthesis will have limited effect on increasing NAD + levels, as elevated CD38 continues to degrade NAD +
What you will Learn What is B12 Describe the signs and symptoms of pernicious anaemia Describe pernicious anaemia and its impact on patients Fully understand the principles, and practice B12 deficiency and B12 injections Describe why people require B12 injections Demonstrate how to correctly dispose of waste Demonstrate correct infection control procedures and the use of PPE Describe when patients require a referral and understand the importance of referral using correct clinical pathways Understand the need for correct prescribing procedures Blood- function B12 Deficiency Causes of B12 deficiency B12 injections and common side effects Maintenance & aftercare Procedure specific Health & Safety Terms & conditions apply Current investment: 295 Booking Fee Just: 150
ISBN 978-0-306-46820-9.
Heres what the clinical evidence shows: Study Scope: 900+ participants across 6 randomized, double-blind, placebo-controlled trials Safety Profile: Indistinguishable from placebo in tolerability assessments Serious Events: Zero serious adverse events attributed to AOD-9604 Withdrawals: No treatment-related discontinuations in any trial Common Effects: Mild headache and minor GI symptoms at rates similar to placebo IGF-1 Impact: No effect on insulin-like growth factor-1 levels Metabolic Safety: No negative impact on glucose metabolism or insulin sensitivity Immunogenicity: Zero participants developed anti-AOD9604 antibodies The following analysis provides complete details on the clinical trial evidence supporting AOD-9604s favorable safety profile
